Maier, Andrea http://orcid.org/0000-0002-3427-4806
Kapfenberger, Romina
Katona, Istvan http://orcid.org/0000-0002-0955-8911
Weis, Joachim http://orcid.org/0000-0003-3280-6773
Schulz, Jörg B. http://orcid.org/0000-0002-8903-0593
Rolke, Roman http://orcid.org/0000-0002-7370-8574
Funding for this research was provided by:
RWTH Aachen University
Article History
Received: 9 June 2022
Revised: 12 August 2022
Accepted: 14 August 2022
First Online: 9 September 2022
Declarations
:
: All other authors declare that they have no conflict of interest for the content of this paper. RR: Financial interests: Grants: Interdisciplinary Centre for Clinical Research within the Faculty of Medicine at the RWTH Aachen University (IZKF TN1-6, 532006). Funds: BMBF consortium “Bio2Treat” (German Federal Ministry of Education and Research/Bundesministerium für Bildung und Forschung, BMBF, “Chronische Schmerzen – Innovative medizintechnische Lösungen zur Verbesserung von Prävention, Diagnostik und Therapie,” contract number 13GW0334B). Speaker fees or honoraria for counselling services from: Aristo Pharma, Cannamedical, Grünenthal, Lilly & Company, Tilray Germany, Spectrum Therapeutics. Non-financial interests: none. JBS: Financial interests: speaker honoraria and honoraria for participation in advisory boards from Biogen, Roche, and Novartis. Non-financial interests: none. AM: Financial interests: grants: Takeda Pharmaceuticals, Standing Up to POTS Research Fund, Centogene GmbH. Non-financial interests: advisory boards: Deutsche EDS Initiative and PoTS und andere Dysautonomien.
: This study was performed in accordance with the Declaration of Helsinki and good clinical practice and approved by the Institutional Review Board of RWTH Aachen University (EK 101/15, EK101/17, EK 031/17, EK101/18 and EK 092/19) in a retrospective manner.
: In some cases, data from our prospective registry (EK 092/19) were included, and then patients gave their written informed consent before inclusion in the registry.